Figure 2From: DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer Kaplan-Meier curves are shown comparing the progression free survival of patients with different epigenotypes of SFRP5 (A), WIF1 (B), different genotype of EGFR (C), or SFRP5 in adenocarcinoma with EGFR mutation group (D). Back to article page